Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with chronic hepatitis C (CHC)~* Participants with HCV genotype 1~* Participants who, at the time of the study, are referred to the Hospital Pharmacy Service to begin treatment with PEG and RBV for 48 weeks~* Available to understand and to give Informed Consent~Exclusion Criteria:~- Participants co-infected with Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG + RBV (Standard Clinical Practice) (Type: None): Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).